Abiraterone acetate improves survival in metastatic castration-resistant prostate cancer
Wednesday, October 13, 2010 - 09:20
in Health & Medicine
Patients with metastatic castration-resistant prostate cancer who have progressed after chemotherapy live significantly longer if treated with the drug abiraterone acetate compared to placebo, the results of a large Phase-III clinical trial confirm...